Background. There is growing evidence that beta-blockade may reduce mortality in selected patients with sepsis. However, it is unclear if a pre-existing, chronic oral beta-blocker therapy should be continued or discontinued during the acute phase of severe sepsis and septic shock. Methods. The present secondary analysis of a prospective observational single centre trial compared patient and treatment characteristics, length of stay and mortality rates between adult patients with severe sepsis or septic shock, in whom chronic beta-blocker therapy was continued or discontinued, respectively. The acute phase was defined as the period ranging from two days before to three days after disease onset. Multivariable Cox regression analysis was performed to compare survival outcomes in patients with pre-existing chronic beta-blockade. Results. A total of 296 patients with severe sepsis or septic shock and pre-existing, chronic oral beta-blocker therapy were included. Chronic beta-blocker medication was discontinued during the acute phase of sepsis in 129 patients and continued in 167 patients. Continuation of beta-blocker therapy was significantly associated with decreased hospital (P¼0.03), 28-day (P¼0.04) and 90-day mortality rates (40.7% vs 52.7%; P¼0.046) in contrast to beta-blocker cessation. The differences in survival functions were validated by a Log-rank test (P¼0.01). Multivariable analysis identified the continuation of chronic betablocker therapy as an independent predictor of improved survival rates (HR ¼ 0.67, 95%-CI (0.48, 0.95), P¼0.03). Conclusions. Continuing pre-existing chronic beta-blockade might be associated with decreased mortality rates up to 90 days in septic patients.
The high prevalence of cardiovascular diseases leads to an increasing proportion of hospital patients taking chronic oral betablocker therapy. 1 Physicians have to decide on a daily basis whether or not to continue chronic beta-blocker medication and these decisions can markedly influence outcome. For example, continuing chronic beta-blocker therapy has been associated with reduced mortality in patients with acute respiratory failure. 2 In septic patients, limiting beta-adrenergic stimulation may also be beneficial. 3 In a randomized controlled trial, a newly initiated esmolol infusion in fluid resuscitated septic shock patients with tachycardia increased stroke volume, reduced norepinephrine and fluid requirements and lowered 28-day mortality rate. 4 Furthermore, a pre-existing chronic betablocker therapy was associated with improved 28-day survival despite a higher risk profile in this cohort. 5 However, whether oral beta-blockers were continued or not during sepsis in that study is unknown. Notably, current guidelines give no recommendation how to manage chronic beta-blocker medication during sepsis. 6 The primary aim of the present study was to compare 90-day mortality rates for discontinued or continued chronic betablocker therapy in patients with severe sepsis and septic shock. Secondary outcomes included length of stay, ICU (intensive care unit), hospital and 28-day mortality.
Methods

Design
The present secondary analysis of a single-centre prospective observational trial 7 on critically ill patients with severe sepsis or septic shock was performed at an interdisciplinary, surgical ICU of the tertiary University Hospital of Greifswald, Germany. The original study was conducted as part of the local quality improvement program for the improvement in diagnosis and treatment in patients with severe sepsis or septic shock. Data were entered into a study database (Sepsis Information System for Quality Assurance, SIQ; G.punkt Medical Services, Magdeburg, Germany). The local ethics committee approved the study (Identifier: BB 133/10) and waived a written informed consent because of the observational nature of this quality improvement initiative and the anonymous data collection. The study was performed from January 1 
Study population
During the study period, all patients of the ICU were screened daily by study nurses for the first episode of a systemic inflammatory response syndrome (SIRS) and at least one organ dysfunction within the last 24 h. SIRS, organ failure, severe sepsis and septic shock were defined according to ACCP/SCCM consensus criteria. 8 SIRS was diagnosed if at least two of the following criteria were fulfilled: body temperature >38 C or <36 C, heart rate >90 min À1 , respiratory failure with a respiratory rate >20 min À1 or a partial carbon dioxide pressure of <4.3 kPa and a white blood cell count of >12,000 cells mL À1 or <4000 cells mL À1 or the presence of more than 10% immature neutrophils. Organ dysfunctions were defined as systolic bp below 90 mm Hg in the absence of other causes and despite adequate fluid resuscitation, lactate acidosis (>1 mmol L À1 ), oliguria (urine output <0.5 mL kg À1 h À1 for at least two h despite adequate fluid resuscitation) or an acute alteration in mental status. In a second step, the records were screened for signs of severe sepsis (to specify organ failure) or septic shock (hypotension or need of catecholamines despite adequate fluid replacement) and for the focus of infection (microbiological probes, Xrays etc.). Experienced intensivists in the study team (4 consultants) reviewed every case and decided based on all available documents whether SIRS and organ failure were probably caused by an infection or not. The study team did not change during the study period. All patients aged!18 yr, who met the criteria for the first episode of severe sepsis or septic shock, were included in the study. A second episode of sepsis was not registered to exclude phenomena such as the compensatory anti-inflammatory response syndrome. 9 
Definitions
The onset of sepsis was defined as the first time point when patients fulfilled the ACCP/SCCM criteria for severe sepsis or septic shock. 8 The onset of severe sepsis or septic shock was identified retrospectively by study nurses and validated by intensivists based on laboratory and haemodynamic variables and notes in the patient management system. The place where sepsis was deemed to have occurred was determined according to dates of onset of sepsis, admission to hospital and ICU. Community-acquired sepsis was defined as an infection that occurred <48 h after hospital admission. ICUacquired sepsis was defined as an infection >48 h after ICU admission. Otherwise, sepsis was categorised as hospital-acquired sepsis. Pre-existing chronic health problems were defined as at least one of the following: chronic kidney failure, metastatic cancer, haematological malignancies, AIDS, other causes of immunosuppression, severe hepatic failure, NYHA class IV and pre-existing chronic severe hypoxia.
The electronic patient management system or the patient's documents were reviewed, or the general practitioner was contacted to find which patients were receiving chronic betablocker medication. Pre-existing oral beta-blocker therapy was defined as a treatment started at least seven days before sepsis onset. The individual indications for beta-blockers could not be evaluated in detail but maybe inferred from the comorbidities ( Table 1 ). Discontinuation was defined as an interruption of a pre-existing beta-blocker therapy for more than 24 h within the acute phase of severe sepsis and septic shock. The acute phase of severe sepsis and septic shock was narrowly defined as the period ranging from two days before to three days after sepsis onset, to evaluate the impact of beta-blockade during the period of highest haemodynamic instability and highest sympathetic tone.
Mortality rates were determined in ICU, hospital, and 28 days and 90 days after sepsis onset. Study nurses determined Editor's key points
• Evidence is emerging that beta-blockade may be beneficial in some patients with sepsis.
• In this study there was an association between continuation of beta-blocker and decreased in-hospital, 28-day and 90-day mortality in patients with sepsis.
• However, the data are from a retrospective secondary analysis of a single centre study, with possible confounding factors.
• These results add to the evidence that beta-blockade may influence outcome in sepsis but should be interpreted with caution. 
Study groups
Based on the presence of an oral pre-existing chronic betablocker therapy and its management during the acute phase of severe sepsis and septic shock two groups of patients were defined:
• Discontinued: pre-existing chronic beta-blocker therapy, but administration was discontinued or paused for more than 24 h during the acute phase of severe sepsis and septic shock • Continued: pre-existing chronic beta-blocker therapy that was continued during the acute phase of severe sepsis and septic shock
Study endpoints
The primary goal was to investigate the effects of a continued vs a discontinued pre-existing oral beta-blocker therapy during the acute phase of severe sepsis and septic shock on 90-day mortality. Secondary endpoints included mortality rates 28 days after sepsis onset, during hospital and ICU stay and lengths of stay (LOS).
Statistical analysis
Statistical analyses were performed using MATLAB R2016a (Natick, Massachusetts) and GNU R version 3.3.1 (Language and Environment for Statistical Computing, R Core Team, Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics are provided by counts and percentages for categorical data. Because of skewness numerical data are expressed as median and interquartile range. Table 1 additionally includes means, standard deviations and 95% Clopper-Pearson confidence limits for the mean (95%-CI) for lengths of stay to facilitate comparisons with previous clinical trials. Two-tailed P values were represented to compare the pre-existing presence of an oral beta-blockade during the acute phase of severe sepsis and septic shock ('discontinued' vs 'continued'). Therefore, Fisher's exact tests for categorical features with two levels, v 2 tests for categorical features with more than two levels and Student's t-test or Wilcoxon-Mann-Whitney U-test for numerical data were performed. Missing values were omitted for the descriptive part. The number of missing values is listed in the supplementary material (Supplementary Table S1 ). The survival functions were computed using the Kaplan-Meier estimator and a Log-rank test was performed.
The multivariable Cox model consists of variables representing disease severity at sepsis onset (APACHE II score, sepsis severity, site of infection, chronic diseases, heart rate, body temperature, lactate level, white blood cells, C-reactive protein, procalcitonin) and baseline characteristics (age, sex, known nosocomial pathogen, hospital-acquired infection, antibiotic therapy before sepsis onset, coronary heart disease, pre-existing administration of statins and angiotensin converting enzyme inhibitor and/or angiotensin receptor blocker) to reduce the indication bias. Numerical data (age, body temperature, lactate level, white blood cells, C-reactive protein and procalcitonin) were transformed into categorical variables in order to take the nonlinear influence of this features into account. This was executed based on reference ranges and restricted cubic splines. The categorization and the restricted cubic spline estimation are illustrated in the Supplementary material ( Supplementary  Fig. S1 ). The proportional hazards assumption for the Cox regression model was verified visually by graphs of the scaled Schoenfeld residuals and v 2 tests were performed. To handle the problem of overfitting a cross-validated LASSO for Cox regression models 11 was performed in R using "cv.glmnet" of the "glmnet"-package. 12 
Results
During the four-yr study period 6473 ICU patients were screened. After exclusion of patients younger than 18 yr, patients without infection and chronic beta-blocker therapy and those not fulfilling the criteria for severe sepsis or septic shock, 296 patients were included: 73 with severe sepsis (25%) and 223 with septic shock (75%). Beta-blockers were continued during the acute phase of severe sepsis and septic shock in 167 patients and discontinued in 129 patients (Fig. 1) . Chronic beta-blocker treatment included cardioselective agents (ß 1 ) (atenolol, bisoprolol, metoprolol, nebivolol, talinolol) and nonselective agents (b 1 þ 2 ) (carvedilol, propranolol, sotalol).
Patients' characteristics
Patients' clinical and therapeutic characteristics are presented in Table 1 . Compared with patients with a continued betablocker therapy patients of the discontinued group were younger (P¼0.02) but had increased SAPS II scores (P<0.01) and lactate concentrations at onset of sepsis (P<0.01). There were no significant differences between both groups with respect to origin (P¼0.99), site of infection (P¼0.10) or chronic disease (P¼0.64). Pre-existing statins therapy was more frequent in patients with continued beta-blockade (P¼0.04). Continuation of chronic betablocker therapy was not associated with an increased need for vasopressor or inotropic support, nor use of low-dose steroids (P>0.05 each), but was associated with reduced requirements of crystalloids during the first 24h (P¼0.049).
Mortality rates and length of stay
Hospital, 28-day and 90-day mortality rates were significantly increased in patients with discontinued beta-blocker therapy as compared with beta-blocker continuation (P<0.05 each), but the difference in ICU mortality was not statistically significant (P¼0.06). Though median ICU LOS after diagnosis was longer in patients with continued vs discontinued beta-blocker medication (P¼0.02), there was no statistical difference in hospital LOS (P¼0.54) ( Table 1) .
Survival analysis
Continued beta-blockade was associated with a decreased mortality rate (Log-rank test: P¼0.01) (Fig. 2) . Indeed, when other covariates were considered using multivariable Cox regression analysis there was an association between continuation of chronic beta-blocker therapy and hazard rate for survival (HR ¼ 0.67, 95%-CI ¼ (0.48, 0.95), P¼0.03) ( Table 2 ).
Discussion
The main results of the present secondary analysis of a prospective observational trial suggest that continuing a pre-existing chronic oral beta-blocker therapy during the acute phase of severe sepsis or septic shock, is associated with decreased mortality rates up to 90 days, compared with patients with discontinued beta-blocker treatment. In addition, multivariable Cox proportional analysis identified the continuation of chronic beta-blocker therapy as an independent predictor of decreased 90-day mortality. Beta-blockers have been shown to provide beneficial effects by limiting the adrenergic stress response in numerous subgroups of critically ill patients, such as burns 13 14 , trauma 15 17 Despite this encouraging background, treating septic patients requiring vasopressor therapy to stabilize haemodynamics and potentially suffering from sepsis induced myocardial dysfunction with a negative chronotropic and inotropic drug seemed to be not advisable 18 and currently does not represent the standard of care. 19 However, after a successful pilot study 4 Morelli and colleagues 20 demonstrated in a randomized controlled trial that a titrated infusion of the short acting b 1 -selective beta-blocker esmolol optimized stroke volume, reduced norepinephrine and fluid requirements and improved renal function in patients with septic shock. The present data might support the haemodynamic tolerance of beta-blocker therapy in fluid resuscitated patients with severe sepsis and septic shock, because there was not an increased need for vasopressor or inotropic support in the continued vs the discontinued group. Notably, the continuation of beta-blockade was associated with reduced fluid requirements; further supporting an improved haemodynamic stability as suggested by Morelli. 20 21 However, data on haemodynamic effects of beta-blockers in sepsis are inconsistent. In a small, uncontrolled, prospective study including 10 septic patients a continuous esmolol infusion decreased heart rate but did not improve stroke volume or reduce norepinephrine requirements.
22
Chronic beta-blocker medication has been reported to be associated with an improved outcome in critically ill patients in general 23 and specifically in septic patients. 5 24 But these studies did not evaluate if beta-blockers were continued or discontinued during ICU or hospital stay. 5 23 24 Consequently, no conclusions about therapeutic consequences could be derived from these studies, because at the diagnosis of sepsis, pre-existing medication cannot be changed. Notably, in an ICU population with hypoxaemic respiratory failure the cessation of a chronic beta-blocker therapy within the first 24 h has been reported to be associated with higher mortality but patients with sepsis were excluded from this study. 2 25 The present data suggest an association between the continuation of chronic beta-blockade during the acute phase of severe sepsis and septic shock and reduced mortality rates up to 90 days compared with discontinuation. Potential explanations include the suppression of highly elevated sympathetic tone during the acute phase of sepsis and/or rebound phenomena after beta-blocker withdrawal. In addition to b 1 -receptor mediated haemodynamic effects, further mechanisms of beta-blockers suggested by experimental studies include the b 2 -receptor mediated modulation of inflammation, 26 27 coagulation 28 and metabolism. 29 30 Because of the retrospective nature of the present analysis and the fact that just four patients were treated with a nonselective beta-blocker, we cannot elaborate on the underlying mechanisms.
There are some limitations of this study. The retrospective analysis of an existing database results in potentials for confounding and indication bias. For example, we do not have sufficient information about the indication for cessation or continuation of chronic beta-blockade. As there are currently no recommendations how to handle chronic beta-blocker therapy by national and international sepsis guidelines, the decision how to manage chronic beta-blocker treatment was made by the intensivists in charge individually for each patient. To statistically reduce the risk of confounding and particularly to reduce the indication bias a multivariable Cox regression analysis was performed. Nevertheless, the observational and retrospective study design only allows us to generate hypotheses that need to be confirmed in future prospective trials. The increased SAPS II scores and lactate levels at sepsis onset in the discontinued vs continued group potentially suggest a higher disease severity in patients of the discontinued group. This assumption is challenged by similar APACHE scores and younger patients in the discontinued group, both representing established predictors of worse outcome. 31 The lower lactate levels potentially are a consequence of the continued betablocker therapy as suggested by a retrospective study reporting decreased lactate levels in patients with beta-blocker therapy as compared with those without. 24 Of note, the proportion of septic shock patients in this study is especially high. This might be explained by local circumstances. The study site is a tertiary university hospital and a regional referral centre for the treatment of patients with sepsis. Additionally, several departments of the hospital take care of patients with sepsis and severe sepsis on their intermediate care units. Only in cases of further deterioration patients are transferred to the ICU.
The acute phase of severe sepsis and septic shock was defined narrowly from two days before until three days after sepsis onset. Consequently, it cannot be excluded that patients in the discontinued group received their beta-blocker medication after this period. At first sight, this appears to represent a limitation, because beta-blockers might not have been discontinued during the complete phase of sepsis. However, even interrupting chronic beta-blocker therapy for only a few days was associated with a significantly worse outcome.
Conclusions
These data suggest that discontinuation of a pre-existing chronic beta-blockade during severe sepsis and septic shock is associated with increased mortality. Conversely, continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock might be associated with decreased mortality rates up to 90 days. These results are hypothesis-generating and require verification in prospective trials.
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